Sticking It to Cancer with Molecular Glue for SHP2

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Protein-tyrosine phosphatases (PTPs) are crucial regulators of cellular signaling.
• Dysregulation of PTPs is implicated in various diseases, including cancer.
• Developing specific PTP inhibitors has proven difficult due to challenges in achieving selectivity and bioavailability.

Purpose of the Study:

• To explore novel strategies for developing effective protein-tyrosine phosphatase (PTP) inhibitors.
• To investigate the potential of allosteric inhibition for targeting PTPs.
• To assess the efficacy of a specific, orally bioavailable SHP2 inhibitor in vivo.

Main Methods:

• Literature review of PTP inhibitor development efforts.
• Analysis of a recent report detailing a novel SHP2 inhibitor.
• Evaluation of in vivo activity data for the identified inhibitor.

Main Results:

• Previous attempts to develop PTP inhibitors have largely been unsuccessful.
• A new report describes a highly specific, orally bioavailable inhibitor targeting the SHP2 oncoprotein.
• This SHP2 inhibitor demonstrates in vivo activity, validating the allosteric approach.

Conclusions:

• Allosteric modulation represents a promising avenue for overcoming previous limitations in PTP inhibitor development.
• The successful development of an orally bioavailable SHP2 inhibitor highlights the potential of targeting PTPs via allosteric mechanisms.
• This approach may pave the way for new therapeutic strategies targeting diseases driven by PTPs.